Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer

Overview of attention for article published in Urologic Oncology, November 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#42 of 2,921)
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets
blogs: 1 blog

twitter: 4 X users
guideline: 2 clinical guideline sources

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 4,451 followers.

RT @MarkTysonMD: Long-term FU for 34 pts with bcg-unresponsive #bladdercancer treated with gem/doce shows HG-RFS of 67%, 50%, and 37% at 1y…

Very similar experience in our much smaller cohort

RT @MarkTysonMD: Long-term FU for 34 pts with bcg-unresponsive #bladdercancer treated with gem/doce shows HG-RFS of 67%, 50%, and 37% at 1y…

Long-term FU for 34 pts with bcg-unresponsive #bladdercancer treated with gem/doce shows HG-RFS of 67%, 50%, and 37% at 1yr, 2yr, and 3yr respectively. Our Iowa colleagues Mike O’Donnell and @VigneshPackiam have provided great leadership in this space. ht…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.